efavirenz

efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as part of antiretroviral therapy for the treatment of human immunodeficiency virus type 1. It was a cornerstone of first-line treatment regimens for many years, particularly in resource-limited settings, due to its potent antiviral activity and once-daily dosing. The drug is typically combined with other antiretrovirals, such as tenofovir and emtricitabine, in a single-pill regimen to improve adherence and suppress viral replication.

Medical uses

Efavirenz is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in adults and children over three months of age. It was a key component of preferred regimens recommended by major guidelines, including those from the World Health Organization and the U.S. Department of Health and Human Services, for initial therapy. Its use has been largely supplanted by newer agents like dolutegravir and rilpivirine, which offer improved tolerability and safety profiles. The medication is also used in certain post-exposure prophylaxis protocols following potential occupational exposure to HIV.

Adverse effects

Common adverse effects include rash, dizziness, insomnia, abnormal dreams, and impaired concentration, which often subside after the first few weeks of therapy. More serious concerns include severe psychiatric symptoms such as depression, suicidal ideation, and aggressive behavior, necessitating careful patient monitoring. The drug is associated with significant teratogenicity, classified as Pregnancy Category D by the Food and Drug Administration, and can cause neural tube defects if used during the first trimester. Other notable risks include hepatotoxicity, increases in serum cholesterol and triglycerides, and false-positive results in screening tests for cannabis.

Pharmacology

Efavirenz acts by non-competitively binding to a specific pocket on the HIV-1 reverse transcriptase enzyme, inducing a conformational change that inhibits the conversion of viral RNA into DNA. It is metabolized primarily in the liver by the cytochrome P450 enzymes, notably CYP2B6 and CYP3A4, and is a potent inducer of CYP3A4, leading to numerous drug-drug interactions. The drug is highly protein-bound (>99%) and achieves cerebrospinal fluid concentrations sufficient to potentially impact central nervous system viral reservoirs. Genetic polymorphisms in the CYP2B6 gene, particularly common in populations of African descent, can significantly alter its metabolism and plasma levels.

History

Efavirenz was discovered by scientists at Merck & Co. and was approved for medical use in the United States by the FDA in 1998. Its development represented a significant advance in HIV therapy, offering a potent, once-daily option that simplified complex regimens. The drug was subsequently included in the World Health Organization Model List of Essential Medicines, highlighting its global public health importance. The patent for efavirenz expired in several regions around 2013, facilitating the production of generic versions by companies like Aurobindo Pharma and Cipla, which dramatically increased access in developing countries.

Society and culture

Efavirenz has been a subject of extensive discussion in global health policy, particularly regarding its cost, patent status, and role in large-scale treatment programs like the President's Emergency Plan for AIDS Relief. Its neuropsychiatric side effects have been widely documented in patient communities and were a driving factor behind the shift to newer integrase inhibitors. The drug's teratogenic risk has led to specific recommendations against its use in women of childbearing potential without effective contraception in guidelines from the Centers for Disease Control and Prevention. Its legacy is intertwined with the broader narrative of the global fight against the HIV/AIDS pandemic.

Category:Antiviral drugs Category:HIV/AIDS